Levamlodipine besylate tablets (trade name: Shihuida) are jointly developed by Institute of Applied Chemistry of China Academy of Sciences and Shihuida Pharmaceutical Group Jilin Co., Ltd., which is a high-tech demonstration project supported by Northeast Office of the State Council and National Development and Reform Commission with an investment of 220 million yuan. It is a major scientific research project of China Academy of Sciences in the Ninth Five-Year Plan and the first chiral separation optical pure drug in China. Levamlodipine besylate is a new drug for the treatment of hypertension and angina pectoris, which was approved by the State Administration of Pharmaceutical Products as 1999. Levamlodipine besylate is obtained by removing ineffective and toxic dextrorotators from amlodipine through advanced resolution technology. The patent in Pfizer of the United States proves that "Levamlodipine is more effective than Dexamlodipine 1000 times"; The patent of Sepracor Company in the United States proves that "L-amlodipine avoids the side effects such as limb edema, headache and dizziness caused by racemic amlodipine". Levamlodipine besylate is characterized by high curative effect and extremely low side effects. We have obtained patents from China, the United States, Germany, Britain, France, Canada and Australia, and are applying for Korean patents. Products are exclusively produced in the world.
This product has been randomly and double-blind tested in Peking University People's Hospital, China-Japan Friendship Hospital and other large hospitals 10. It is proved that its curative effect is equivalent to that of imported amlodipine, and the incidence of side effects is reduced by 60%. Nearly 10000 clinical trials were conducted in big hospitals in 26 provinces and cities such as Shanghai, Zhejiang, Hunan, Hubei and Guangdong, and nearly 10,000 hypertensive patients were followed up, which proved that its curative effect was remarkable and its side effects were extremely low. At the same time, its cost performance is extremely high, and its price is lower than that of Loxoxib produced by Pfizer. At present, it has been widely used in more than 2,000 hospitals and more than 7,000 community hospitals in 29 provinces and cities across the country.
Due to the superior product quality, it was awarded the National High-tech Demonstration Project, the Excellent Project of Technological Innovation during the Ninth Five-Year Plan, the Excellent Project Award of Technological Innovation in the Ninth Five-Year Plan, the Science and Technology Progress Award of Jilin Province, the National Key New Product and the Excellent New Product of Jilin Province.